Motley Fool Asset Management LLC Sells 50,749 Shares of DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Motley Fool Asset Management significantly reduced its stake in DexCom by 17.9% in Q1, now holding approximately $15.85 million worth of shares, making it the firm's 24th largest position.
• Several institutional investors, including Golden State Wealth Management and Zions Bancorporation, recently increased their positions in DexCom, indicating a strong institutional interest with over 97.75% of the stock owned by institutions.
• DexCom reported a 15.2% revenue growth compared to last year, with earnings per share of $0.48, surpassing analyst expectations of $0.45, suggesting a positive outlook for the company.

Motley Fool Asset Management LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 232,085 shares of the medical device company's stock after selling 50,749 shares during the quarter. DexCom accounts for 0.9% of Motley Fool Asset Management LLC's investment portfolio, making the stock its 24th largest holding. Motley Fool Asset Management LLC owned 0.06% of DexCom worth $15,849,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC raised its position in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares during the last quarter. Private Trust Co. NA raised its position in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after buying an additional 335 shares during the last quarter. Farther Finance Advisors LLC raised its position in DexCom by 29.3% in the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after buying an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC raised its position in DexCom by 34.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after buying an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC raised its position in DexCom by 944.5% in the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after buying an additional 2,909 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 0.3%

DexCom stock traded down $0.21 during trading hours on Wednesday, reaching $79.96. The company had a trading volume of 4,278,206 shares, compared to its average volume of 3,854,138. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a 50-day moving average price of $83.28 and a 200 day moving average price of $80.19. The firm has a market cap of $31.36 billion, a price-to-earnings ratio of 55.53, a P/E/G ratio of 1.68 and a beta of 1.43. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The business's quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.43 EPS. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president directly owned 109,621 shares in the company, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,656 shares of company stock valued at $2,412,191 over the last quarter. Company insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Barclays increased their price target on DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen lowered DexCom from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group began coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Finally, UBS Group raised their target price on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.